Skip to content

Author

Robert A. Jenders

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Phase 1b study of miricorilant in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH).

BACKGROUND AND AIMS Miricorilant, an oral nonsteroidal selective glucocorticoid receptor modulator, is being investigated as a therapy that modulates hepatic cortisol activity in patients with metabolic dysfunction-associated steatohepatitis (MASH). This phase 1b study evaluated miricorilant's efficacy and safety. AP...

N. Alkhouri, M. Rudraraju, MT Leibowitz et al. · 0 citations
Open access Oct 2026

Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: A multicenter, double-blind, placebo-controlled study.

BACKGROUND AND AIMS Polycystic ovary syndrome (PCOS) is the leading endocrine disorder in reproductive-age women. Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in women with PCOS, but they are underrepresented in MASLD therapeutic trials. We evaluated the safety and efficacy of saroglitazar...

Niharika R. Samala, J. González-González, Robert A. Jenders et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.